Study on Sintilimab in Stage IV High Risk Neuroblastoma
A phase I observational study on the safety and efficacy of treatment of recurrent stage IV high risk neuroblastoma with Nivolumab
Recurrent Stage IV High Risk Neuroblastoma
DRUG: Sintilimab
response, Complete response: (CR): the tumor shrunk more than 50%.

Part of the reaction: (PR): the reduction of tumor body was more than 30%.

No response: (NP): the tumor decreased by less than 30% or increased., 2 years after taking the drug
side effect, Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, 2 years after taking the drug
Mutation, Mutation load, high microsatellite instability (MSI-H) or mismatch repair defect (dMMR), before taking the drug|programmed death-ligand1 (PD-L1) expression, immunohistochemistry (IHC) test for PD-L1 and cluster of differentiation 8 (CD8) expression in tumor tissue, before taking the drug
A phase I observational study on the safety and efficacy of treatment of recurrent stage IV high risk neuroblastoma with Nivolumab